-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Trastuzumab Biosimilar in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Biosimilar in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bevacizumab Biosimilar in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bevacizumab Biosimilar in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bevacizumab Biosimilar in Non-Small Cell Lung Cancer Drug Details:...
-
Company Insights
Innovation and Patenting activity of Prestige Consumer Healthcare Inc Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Prestige Consumer Healthcare Inc Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LB-100 in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LB-100 in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LB-100 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: LB-100...
-
Product Insights
Cytokine Release Syndrome (Cytokine Storm) – Drugs In Development, 2023
Global Markets Direct’s, ‘Cytokine Release Syndrome (Cytokine Storm) - Drugs In Development, 2023’, provides an overview of the Cytokine Release Syndrome (Cytokine Storm) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cytokine Release Syndrome (Cytokine Storm), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Hemolytic Uremic Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Hemolytic Uremic Syndrome - Drugs In Development, 2023’, provides an overview of the Hemolytic Uremic Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hemolytic Uremic Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Hemoglobinuria – Drugs In Development, 2023
Global Markets Direct’s, ‘Hemoglobinuria - Drugs In Development, 2023’, provides an overview of the Hemoglobinuria pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hemoglobinuria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Paroxysmal Nocturnal Hemoglobinuria – Drugs In Development, 2023
Global Markets Direct’s, ‘Paroxysmal Nocturnal Hemoglobinuria - Drugs In Development, 2023’, provides an overview of the Paroxysmal Nocturnal Hemoglobinuria pipeline landscape. The report provides comprehensive information on the therapeutics under development for Paroxysmal Nocturnal Hemoglobinuria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Atypical Hemolytic Uremic Syndrome (Nondiarrhea – Associated Hemolytic Uremic Syndrome) – Drugs In Development, 2023
Global Markets Direct’s, ‘Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Drugs In Development, 2023’, provides an overview of the Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers...
-
Product Insights
Retinopathy – Drugs In Development, 2023
Global Markets Direct’s, ‘Retinopathy - Drugs In Development, 2023’, provides an overview of the Retinopathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Retinopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...